排序方式: 共有16条查询结果,搜索用时 15 毫秒
1.
2.
海捷亚和卡托普利对高血压并发心衰的疗效比较 总被引:1,自引:1,他引:1
目的:观察血管紧张素Ⅱ受体阻滞剂海捷亚的降压疗效和对心功能的影响.方法:所有患者在观察期间原抗心衰药物(洋地黄制剂,利尿剂)不变.海捷亚组(40例)口服海捷亚每日1片,连用4周;卡托普利组(36例)口服卡托普利12 5~25 mg,每日2~3次,连用4周,用药前和用药后行超声心动图计算射血分数(EF)和E/A比值,评定用药前后心功能变化.结果:两组治疗4周后,心功能都有明显改善,海捷亚组总有效(显效 有效)率为82%,卡托普利组为66%,两组间相比,海捷亚组明显好于卡托普利组.结论:心衰患者使用海捷亚有利于缓解心衰症状,改善其收缩功能和舒张功能;其疗效优于卡托普利. 相似文献
3.
氯沙坦(科素亚)是血管紧张素Ⅱ受体(AT_1)拮抗剂,是高血压药物治疗上的重要进展,其降压确实,副作用少,依从性好。吲哒帕安亦是新型利尿降压药。本文研究的目的是观察氯沙坦与吲哒帕安单用或合用的降压疗效。 相似文献
4.
将152例原发性高血压(EH)并心力衰竭(HF)患者随机分为观察组80例和对照组72例,两组观察期间原抗心衰药物(洋地黄制剂,利尿剂)用法不变,观察组在此基础上每日上午口服国产坎地沙坦酯片,8 m g/次,连用4周;对照组口服卡托普利,12.5~25 m g/次,2~3次/d,连用4周。观察两组心率、血压、心功能变化及血浆内皮素(ET)、血小板α-颗粒膜蛋白(GM P-140)水平变化。结果观察组心功能明显改善、心率和血压降低、血浆ET和GM P-140水平降低,效果明显优于对照组。证实国产坎地沙坦酯治疗EH并HF可有效控制血压,改善心脏功能;可能机制为改善血管内皮功能、抑制血小板聚集。 相似文献
5.
黄芪注射液合并小剂量尿激酶治疗不稳定性心绞痛56例 总被引:12,自引:0,他引:12
1996年5月~1997年3月,我们用黄芪注射液合并小剂量尿激酶治疗56例冠心病不稳定性心绞痛取得较好疗效,现报告如下。临床资料 106例住院患者,均符合冠心病不稳定性心绞痛的诊断标准(JAmCollCardiol1995;26∶313),且于入院前胸痛发作次数增多,而在入院前24h内休息时亦有胸痛发作或近1周内胸痛发作间歇期<48h。所有患者排除应用溶栓剂和抗凝剂的禁忌症,同时排除中重度充血性心衰、长期服用华法令(抗凝剂)及明显肝肾功能损害者。按入院的单日或双日随机分为黄芪组和对照组,前者56例(男33例,女23例),年龄37~69岁(平均48±11岁)… 相似文献
6.
厄贝沙坦对高血压并发心力衰竭患者心功能的影响 总被引:1,自引:0,他引:1
目的 :观察血管紧张素Ⅱ受体阻滞剂厄贝沙坦的降压疗效和对心功能的影响。方法 :试验组 (n =4 0 )口服厄贝沙坦 15 0mg ,qd ,连用 4周 ;对照组 (n =36 )口服卡托普利 12 .5mg ,bid或tid ,连用 4周 ,用药期间仔细检查体格及心电图 ,给药前后行超声心动图计算射血分数 (EF)和E/A比值 ,评定心功能变化。结果 :试验组SBP和DBP都有明显降低 ,而对照组改变不明显 ,2组间比较差异非常显著 ;2组治疗后心功能都有明显改善 ,试验组总有效率为 80 % ,对照组为 6 1% ,2组比较差异有显著性 ;2组治疗后LVEF均升高 :试验组 0 .4 6± 0 .0 7vs 0 .4 1±0 .0 6 (P <0 .0 5 ) ,对照组 0 .4 2± 0 .0 6vs 0 .4 0± 0 .0 5 (P >0 .0 5 ) ;E/A比值升高 :试验组为 1.0 6± 0 .13vs 0 .5 8±0 .15 (P <0 .0 1) ,对照组 0 .76± 0 .12vs 0 .5 7± 0 .14 (P <0 .0 5 )。试验组好转更明显。结论 :厄贝沙坦有利于缓解心衰症状 ,改善其收缩功能和舒张功能 ;其疗效优于卡托普利。 相似文献
7.
8.
目的:观察辛代他汀对高甘油三酯血症的影响。方法:血清甘油三酯水平在2.24~6.78mmol/L(200—600mg/dL)的病人140例(男性82例.女住58例,年龄55±9岁)随机分为辛代他汀组和对照组。前者72例(男42例,女30例).年龄56±10岁,每晚服用辛伐他汀20mg,连用8周,后者68例(男性40例,女性28例)年龄55±8岁,服用吉非诺齐300mg,tid,连用8周。结果:辛代他汀连用4~8WK明显降低血清高三酰甘油水平。亦降低血清LDLC水平,而且其作用明显强于吉非罗齐。结论:辛伐他汀对高三酰甘油血症有显效.特别适合于混合性高脂血症者。 相似文献
9.
Effect of Xuesaitong Soft Capsule(血塞通软胶囊)on Hemorrheology and in Auxiliarily Treating Patients with Acute Cerebral Infarction
下载免费PDF全文
![点击此处可从《中国结合医学杂志》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊,XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group ( n = 96) and the treated group ( n = 108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrhe.ological indexes were measured before and after treatment. Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group (66.7%) was significantly higher than that in the control group (27.1%, P<0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 inthem evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored. 相似文献
10.